logo

For the Inventor, By the Inventor

Geneva, Switzerland

Robert Johannes Lutjens

This inventor holds 8 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Janssen Pharmaceuticals, Inc., Addex Pharma, S.a., Addex Pharmaceuticals S.a.. Active years: 2012-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Johannes Lutjens. Retrieved from https://idiyas.com/inventor/robert-johannes-lutjens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 12.5

 

Average Co-Inventor Count = 6.7

ph-index = 3

Forward Citations = 79(Granted Patents)


Company Filing History:

goldMedal8 out of 161 
 
Janssen Pharmaceuticals, Inc.
 patents
silverMedal7 out of 37 
 
Addex Pharma, S.a.
 patents
bronzeMedal1 out of 3 
 
Addex Pharmaceuticals S.a.
 patents
where one patent can have more than one assignee

Years Active: 2012-2016

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 9266834 - 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors (2016-02-23),
2. 9114138 - [object Object] (2015-08-25),
3. 9067891 - 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors (2015-06-30),
4. 8841323 - 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors (2014-09-23),
5. 8748621 - [object Object] (2014-06-10),
6. 8722894 - 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones (2014-05-13),
7. 8399493 - Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors (2013-03-19),
8. 8252937 - [object Object] (2012-08-28),

Title: Robert Johannes Lutjens: A Pioneer in Pharmacological Innovations

Introduction:

Robert Johannes Lutjens is a distinguished inventor based in Geneva, Switzerland, renowned for his groundbreaking work in the field of pharmacology. With a portfolio of 8 patents to his name, he has significantly contributed to the advancements in neurological and psychiatric disorder treatments.

Latest Patents:

Lutjens' latest patent pertains to the development of 1, 4-disubstituted 3-cyano-pyridone derivatives as positive allosteric modulators of MGLUR2-receptors. These compounds play a pivotal role in the treatment and prevention of various central nervous system disorders, including anxiety, schizophrenia, migraine, depression, and epilepsy.

Career Highlights:

Having worked with esteemed companies such as Janssen Pharmaceuticals, Inc. and Addex Pharma S.A., Lutjens has honed his expertise in drug discovery and development. His innovative approach has led to the creation of novel pharmacological compounds that have the potential to revolutionize the treatment landscape for neurological and psychiatric disorders.

Collaborations:

Throughout his career, Lutjens has collaborated closely with industry peers, including Jose Maria Cid-Nunez and Andres Avelino Trabanco-Suarez. Together, they have shared insights, expertise, and ideas to drive innovation and bring novel pharmaceutical solutions to fruition.

Conclusion:

In conclusion, Robert Johannes Lutjens stands as a beacon of innovation in the field of pharmacology, inspiring future generations of inventors to push the boundaries of what is possible in drug development. His contributions to the medical field are invaluable, and his patents serve as a testament to his unwavering dedication to improving the quality of life for individuals affected by neurological and psychiatric disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…